The Future of Pharma

SWISS MADE
Investors
We offer qualified investors the opportunity to participate in the success of MediCrops with an investment sum of CHF 100,000 or more.
More informations
Career

Chief Marketing Officer - exciting position

Have you always wanted to build something big and successful? Would you like to be part of a successful and internationally growing team that sets new standards in the pharmaceutical industry?
Invest

Detailed Info - Reports & Publications

Read the latest reports and publications and analyse the potential of our market.
Media

News & MediCrops in the press

Interviews, press articles and specialist articles on MediCrops Holding AG and its products.
Production

Highly integrated production process

MediCrops offers its customers premium quality and dependable products based on a highly integrated production process and strict product quality standards.

Harnessing the potential of medicinal cannabis

Leading manufacturer

MediCrops, based in Switzerland, is one of, if not the leading research and development company.  The premium quality medicinal cannabis products are made for the European market, with a focus on the German-speaking region.

More about MediCrops

Medicinal cannabis and MediCrops

Market development of medicinal cannabis in Europe by country (in millions of euros)

Medicinal cannabis market

Cannabis is cultivated and exported worldwide. Cultivation in Europe often takes place in so-called indoor facilities, especially in Germany, the Netherlands and Italy.

The responsible Committee of the Council of States, i.e. the body that represents the cantons in the Swiss parliament, has given the green light by a clear majority for cultivation, production, trade and consumption to be newly regulated. Accordingly, the Narcotics Act will be amended to facilitate the distribution of cannabis for medicinal purposes and to allow its export.

This has created the basis for a regulated and legal cannabis market in Switzerland with great growth potential.

More on the market

One of the most promising markets of the future

Biggest Global
Growth Market:
0

BILLIONS OF US DOLLARS
(UP TO 2026)

Global Market
Growth:
0 %

(CAGR 2021–2026)

MediCrops Investment
Requirement:
0

MILLION SWISS FRANCS (BY 2025)

Exponential Growth
MediCrops:
0 %

(CAGR 2022-2025)

Market Potential
in Europe:
0

BILLIONS OF US DOLLARS
(UP TO 2026)

Spectacular Growth
in Europe:
0 %

(CAGR 2021–2026)

Plot Size:
 
0

Square meter

Production Scalability
up to Double:
0

Square meter

More on the market

Be part of the success

Profitable investment

Building on its positioning as a high-quality and fully integrated producer of medicinal cannabis, MediCrops is expected to benefit from the rapidly growing markets in Germany, Austria and Switzerland and gain a significant market share.

For investors

Milestones

0000
0000
0000
  • Market analysis, conception & planning
  • MediCrops® Holding Ltd founded, trademark registered
  • Pilot facility set up in northern Macedonia and start of basic research into cultivation
  • Basic research with extraction in MediCrops’ own laboratory
  • Creation of MediCrops’ own seed bank of cannabis phenotypes
  • Feasibility study and design planning for a modern production facility in Switzerland
  • Foundation of operational subsidiary “MediCrops Biomedical Technologies Ltd”
  • Expansion of management team (CFO and Project Manager)
  • Opening of the Medicrops “Biomedical Competence Center” at Biopôle Startlab, Lausanne (Canton of Vaud)
  • Establishment of a GMP-compliant production facility in Switzerland
  • M&A strategy with focus on the acquisition of a company in the distribution field
  • Commissioning of the production facility according to EU GMP guidelines
  • Sales forecast in double-digit million range
  • Building the digital leadership for medical & recreational use cannabis by introducing digital platforms & marketing
  • Ongoing top line growth with high operating margins due to vertical division and expansion of the value chain and utilization of synergy potentials
  • Initial public offering (IPO) on Sparks at SIX Swiss Exchange
  • Building strong “SWISS”-Brand in Europe